Piramal Pharma Past Earnings Performance
Past criteria checks 2/6
Piramal Pharma's earnings have been declining at an average annual rate of -105.1%, while the Pharmaceuticals industry saw earnings growing at 13.3% annually. Revenues have been growing at an average rate of 14.5% per year. Piramal Pharma's return on equity is 0.6%, and it has net margins of 0.5%.
Key information
-105.1%
Earnings growth rate
-131.2%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | 14.5% |
| Return on equity | 0.6% |
| Net Margin | 0.5% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
₹284 - That's What Analysts Think Piramal Pharma Limited (NSE:PPLPHARMA) Is Worth After These Results
Oct 26
Piramal Pharma (NSE:PPLPHARMA) Takes On Some Risk With Its Use Of Debt
Oct 25Here's Why Piramal Pharma (NSE:PPLPHARMA) Has A Meaningful Debt Burden
Jul 14Estimating The Intrinsic Value Of Piramal Pharma Limited (NSE:PPLPHARMA)
Jun 17We Think That There Are Issues Underlying Piramal Pharma's (NSE:PPLPHARMA) Earnings
May 21It's A Story Of Risk Vs Reward With Piramal Pharma Limited (NSE:PPLPHARMA)
Mar 26Estimating The Fair Value Of Piramal Pharma Limited (NSE:PPLPHARMA)
Feb 28Earnings Update: Here's Why Analysts Just Lifted Their Piramal Pharma Limited (NSE:PPLPHARMA) Price Target To ₹161
Feb 02Calculating The Intrinsic Value Of Piramal Pharma Limited (NSE:PPLPHARMA)
Nov 09Calculating The Fair Value Of Piramal Pharma Limited (NSE:PPLPHARMA)
Aug 11Revenue & Expenses Breakdown
How Piramal Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 87,038 | 453 | 23,310 | 0 |
| 30 Jun 24 | 83,735 | 278 | 22,875 | 0 |
| 31 Mar 24 | 81,712 | 178 | 22,034 | 0 |
| 31 Dec 23 | 78,435 | -333 | 22,171 | 0 |
| 30 Sep 23 | 76,009 | -1,336 | 21,856 | 0 |
| 30 Jun 23 | 74,096 | -1,760 | 21,396 | 0 |
| 31 Mar 23 | 70,816 | -1,865 | 21,046 | 0 |
| 31 Dec 22 | 72,228 | -325 | 20,064 | 0 |
| 30 Sep 22 | 69,535 | 2,210 | 1,409 | 0 |
| 30 Jun 22 | 67,532 | 2,626 | 16,545 | 0 |
| 31 Mar 22 | 67,341 | 3,760 | 15,888 | 0 |
| 31 Mar 21 | 58,868 | 7,708 | 14,762 | 0 |
Quality Earnings: PPLPHARMA has high quality earnings.
Growing Profit Margin: PPLPHARMA became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PPLPHARMA's earnings have declined by 105.1% per year over the past 5 years.
Accelerating Growth: PPLPHARMA has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: PPLPHARMA has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (20.5%).
Return on Equity
High ROE: PPLPHARMA's Return on Equity (0.6%) is considered low.